
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
Collaboration and single-use technologies aided the rapid scale-up of Ebola vaccine manufacturing
over 10 years ago
Measuring and Removing Genotoxic Impuritiesover 10 years ago
Qualification and Validation of Single-Use Shipping Systemsover 10 years ago
Protecting the Product and the Patientover 10 years ago
Deconstructing the Regulatory Spiral





